Target
IDH2
20 abstracts
Abstract
Phase II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors.Org: Radiology and Imaging Services, Sinonasal and Skull Base Tumor Program,
Abstract
Retrospective study of ivosidenib for patients with recurrent IDH mutant gliomas.Org: University of Pittsburgh, University of Pittsburgh Cancer Institute, UPMC Cancer Center - Hillman Cancer Center,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).Org: Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Division of Hematology Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, Division of Medical Oncology, Mayo Clinic,
Abstract
Triple-negative, low-grade gliomas: A highly agressive tumor with dismal prognosis.Org: Timone University Hospital Centre, University of Medicine 'I. Hatieganu' Cluj Napoca, University Hospital Timone, Marseille, France,
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
Comprehensive CRISPR-enabled functional genomics profiling to identify targetable cancer genes in primary acute myeloid leukemia (AML).Org: Function Oncology, San Diego State University Department of Biology, San Diego, CA, Cambridge University Hospitals NHS Foundation Trust,
Abstract
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).Org: University of Kansas Cancer Center, Kansas City, KS, Westwood, The University of Kansas Medical Center, Kansas City, MO, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Methylation-based prediction of myelodysplastic syndrome survival outcomes.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Columbia University - Mailman School of Public Health, Columbia University Medical Center,
Abstract
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,
Abstract
Disparities in uptake of novel therapies for acute myeloid leukemia.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Xenonucleic acid technology in high-sensitivity IDH1/2 mutation detection for glioma molecular profiling.Org: DiaCarta, Inc., National Cancer Institute, Vilnius, Lithuania,
Abstract
Molecular and cytogenetics abnormalities in acute myeloid leukemia at Puerto Rico.Org: San Juan City Hospital-VA Caribbean Healthcare System, VA Caribbean Healthcare System, Auxilio Mutuo Hospital,
Abstract
Whole exome sequencing of sinonasal cancers.Org: The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital, The Ohio State University-James Cancer Hospital Solove Research Institute, The Ohio State University - James Cancer Hospital and Solove Research Institute, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center,
Abstract
Identification of novel actionable SNVs using targeted comprehensive genome profiling in patients with sarcoma.Org: OneCell Dx, Pune, Indiana University – Purdue University Indianapolis, Indx Technology, Cupertino, CA,
Abstract
Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.Org: Data Driven Bioscience, Indiana University – Purdue University Indianapolis, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University Department of General Internal Medicine, Indiana University Hospital,
Abstract
IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, VCU Department of Biostatistics,
Abstract
Incidence of non-canonical IDH mutations and IDH co-mutations in a multicenter prospective study of patients with glioma.Org: Hospital Clinico Universitario San Carlos (IdISSC), Hospital Universitario San Carlos, Hospital Clinico Universitario San Carlos Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Universitario La PaZ (IdiPAZ), Hospital Clínico San Carlos,
Abstract
The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical Universityand Shandong Academy of Medical Sciences, Sino-US Diagnostics Lab,